Tempus AI TEM continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Linda De Jesus, IDT Vice President and General Manager, Global Head of Commercial.

In the US, genome sequencing for newborns is increasing, raising ethical questions about predicting future health risks.

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market ...

Market is expected to reach at a CAGR of 11.6% during the forecast period 2025-2033. The Next Generation Sequencing (NGS) ...

SNS Insider Unveils Strategic Insights into the U.S. Long Read Sequencing Market's Exponential Growth-Valued at USD 220.26 Million in 2023-While the ...

The 1080-gene NGS panel is part of 1Cell.Ai's proprietary OncoIncytes, Cell Biopsy® suite—a comprehensive platform that enables true single-cell resolution of live CTCs and integrates multi ...

OGT, a Sysmex Group company, a leading global provider of clinical and diagnostic genomic solutions, announces the North American launch of its new next-generation sequencing (NGS) SureSeq Myeloid MRD ...

OGT, a Sysmex Group company, a leading global provider of clinical and diagnostic genomic solutions, announces the North American launch of its new next-generation sequencing (NGS) SureSeq Myeloid MRD ...

Next-generation sequencing broad panel assays A range of current precision oncology clinical trials are reliant on customized, targeted NGS-panel assays in order to identify actionable targets.